Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029

M. Surdo; C. Alteri; M. C. Puertas; P. Saccomandi; L. Parrotta; L. Swenson; D. Chapman; G. Costa; A. Artese; E. Balestra; S. Aquaro; S. Alcaro; M. Lewis; B. Clotet; R. Harrigan; H. Valdez; V. Svicher; C. F. Perno; J. Martinez-Picado; F. Ceccherini-Silberstein

doi:10.1016/j.cmi.2014.08.002

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029

M. Surdo, C. Alteri, M. C. Puertas, P. Saccomandi, L. Parrotta, L. Swenson, D. Chapman, G. Costa, A. Artese, E. Balestra, S. Aquaro, S. Alcaro, M. Lewis, B. Clotet, R. Harrigan, H. Valdez, V. Svicher, C. F. Perno, J. Martinez-Picado, F. Ceccherini-Silberstein

Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani

Research output: Contribution to journal › Article › peer-review

Abstract

We characterized maraviroc susceptibility of dual/mixed tropic viruses from subjects enrolled onto phase IIb study A4001029. Maraviroc baseline plasma samples from 13 multidrug-experienced subjects were sequenced and the HIV-1-env gene cloned into pNL4.3Δenv to obtain recombinant viruses. The V3 region was sequenced by the Sanger method and ultradeep sequencing. By analysing subjects having a weighted optimized background therapy susceptibility (wOBT) score of

Original language	English
Journal	Clinical Microbiology and Infection
Volume	21
Issue number	1
DOIs	https://doi.org/10.1016/j.cmi.2014.08.002
Publication status	Published - Jan 1 2015

Keywords

Dual/mixed virus
HIV
maraviroc
phenotypic activity
UDPS

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/j.cmi.2014.08.002

Cite this

Surdo, M., Alteri, C., Puertas, M. C., Saccomandi, P., Parrotta, L., Swenson, L., Chapman, D., Costa, G., Artese, A., Balestra, E., Aquaro, S., Alcaro, S., Lewis, M., Clotet, B., Harrigan, R., Valdez, H., Svicher, V., Perno, C. F., Martinez-Picado, J., & Ceccherini-Silberstein, F. (2015). Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029. Clinical Microbiology and Infection, 21(1). https://doi.org/10.1016/j.cmi.2014.08.002

Surdo, M, Alteri, C, Puertas, MC, Saccomandi, P, Parrotta, L, Swenson, L, Chapman, D, Costa, G, Artese, A, Balestra, E, Aquaro, S, Alcaro, S, Lewis, M, Clotet, B, Harrigan, R, Valdez, H, Svicher, V, Perno, CF, Martinez-Picado, J & Ceccherini-Silberstein, F 2015, 'Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029', Clinical Microbiology and Infection, vol. 21, no. 1. https://doi.org/10.1016/j.cmi.2014.08.002

@article{6fffe25eba384723b30c2710d32cbadd,

title = "Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029",

abstract = "We characterized maraviroc susceptibility of dual/mixed tropic viruses from subjects enrolled onto phase IIb study A4001029. Maraviroc baseline plasma samples from 13 multidrug-experienced subjects were sequenced and the HIV-1-env gene cloned into pNL4.3Δenv to obtain recombinant viruses. The V3 region was sequenced by the Sanger method and ultradeep sequencing. By analysing subjects having a weighted optimized background therapy susceptibility (wOBT) score of ",

keywords = "Dual/mixed virus, HIV, maraviroc, phenotypic activity, UDPS",

author = "M. Surdo and C. Alteri and Puertas, {M. C.} and P. Saccomandi and L. Parrotta and L. Swenson and D. Chapman and G. Costa and A. Artese and E. Balestra and S. Aquaro and S. Alcaro and M. Lewis and B. Clotet and R. Harrigan and H. Valdez and V. Svicher and Perno, {C. F.} and J. Martinez-Picado and F. Ceccherini-Silberstein",

year = "2015",

month = jan,

day = "1",

doi = "10.1016/j.cmi.2014.08.002",

language = "English",

volume = "21",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Effect of maraviroc on non-R5 tropic HIV-1

T2 - refined analysis of subjects from the phase IIb study A4001029

AU - Surdo, M.

AU - Alteri, C.

AU - Puertas, M. C.

AU - Saccomandi, P.

AU - Parrotta, L.

AU - Swenson, L.

AU - Chapman, D.

AU - Costa, G.

AU - Artese, A.

AU - Balestra, E.

AU - Aquaro, S.

AU - Alcaro, S.

AU - Lewis, M.

AU - Clotet, B.

AU - Harrigan, R.

AU - Valdez, H.

AU - Svicher, V.

AU - Perno, C. F.

AU - Martinez-Picado, J.

AU - Ceccherini-Silberstein, F.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - We characterized maraviroc susceptibility of dual/mixed tropic viruses from subjects enrolled onto phase IIb study A4001029. Maraviroc baseline plasma samples from 13 multidrug-experienced subjects were sequenced and the HIV-1-env gene cloned into pNL4.3Δenv to obtain recombinant viruses. The V3 region was sequenced by the Sanger method and ultradeep sequencing. By analysing subjects having a weighted optimized background therapy susceptibility (wOBT) score of

AB - We characterized maraviroc susceptibility of dual/mixed tropic viruses from subjects enrolled onto phase IIb study A4001029. Maraviroc baseline plasma samples from 13 multidrug-experienced subjects were sequenced and the HIV-1-env gene cloned into pNL4.3Δenv to obtain recombinant viruses. The V3 region was sequenced by the Sanger method and ultradeep sequencing. By analysing subjects having a weighted optimized background therapy susceptibility (wOBT) score of

KW - Dual/mixed virus

KW - HIV

KW - maraviroc

KW - phenotypic activity

KW - UDPS

UR - http://www.scopus.com/inward/record.url?scp=84946203838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946203838&partnerID=8YFLogxK

U2 - 10.1016/j.cmi.2014.08.002

DO - 10.1016/j.cmi.2014.08.002

M3 - Article

C2 - 25636934

AN - SCOPUS:84926350750

SN - 1198-743X

VL - 21

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

IS - 1

ER -

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this